On Aug. 4, 2021, Humanigen announced analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19 suggesting Black and African-American patients having a CRP<150 mg/L may be the highest responders to treatment, with a nearly 9-fold increase in likelihood of survival without ventilation.

Humanigen intended to submit data from this analysis for publication in a peer-reviewed journal and present the findings at a medical meeting.